MSD has said it will cut $3 billion off its annual costs by the end of 2027 as it prepares for the end of patent protection for blockbuster cancer drug Keytruda the following year. The plan was ...

Moderna has decided to halt the development of its mRNA-1647 vaccine for congenital cytomegalovirus (CMV) infections – once touted as a future blockbuster – after it failed the Phase 3 CMVictory trial ...

Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 and TGF-beta, as a treatment for advanced gastric cancer. The green light – ...

The EMA's human medicines committee has said it does not recommend approval of Eli Lilly's anti-amyloid Alzheimer's disease treatment Kisunla, saying its modest benefits don't outweigh its risks. The ...

Swiss biotech Oculis is poised to start registration trials for privosegtor, its drug candidate for neuro-ophthalmic diseases, in the wake of encouraging phase 2 data. The Zug-based company said ...

The San Diego biotech has filed a lawsuit against the Japanese drugmaker and its US subsidiary, NS Pharma, claiming that the ...

It is the second licensing deal involving siRNA between GSK and a Chinese biotech in the last few months, coming after the UK ...

J&J has developed two therapies aimed at the estimated two-thirds of MDD patients who continue to experience symptoms despite ...

Novartis said this morning that its pipeline includes more than 30 high-value projects that allow it to achieve sales growth of 6% or more between out to 2029, a point higher than its earlier guidance ...

Daiichi Sankyo has reported its delayed financial results, saying that high spending on third-party manufacturing and a lower-than-expected take-up of its antibody-drug conjugates for cancer led to a ...

Five years after its launch, the FDA’s Project Optimus remained a key theme in discussions at AACR 2026. A dedicated educational session brought together perspectives from regulators, academia, and ...